Discovery of neddylation E2s inhibitors with therapeutic activity

被引:0
|
作者
MAA Mamun
Ying Liu
Yin-Ping Geng
Yi-Chao Zheng
Ya Gao
Jian-Gang Sun
Long-Fei Zhao
Li-Juan Zhao
Hong-Min Liu
机构
[1] Zhengzhou University,Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China; State Key Laboratory of Esophageal Cancer Prevention & Treatment; Key Laboratory of Henan Province for Drug Quality and Evaluation; Institute of Dr
[2] the First Affiliated Hospital of Zhengzhou University,Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy; Department of Pharmacy
[3] the First Affiliated Hospital of Zhengzhou University,Department of Gastrointestinal Surgery
[4] Zhengzhou University,State Key Laboratory of Esophageal Cancer Prevention & Treatment, Academy of Medical Sciences
来源
Oncogenesis | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Neddylation is the writing of monomers or polymers of neural precursor cells expressed developmentally down-regulated 8 (NEDD8) to substrate. For neddylation to occur, three enzymes are required: activators (E1), conjugators (E2), and ligators (E3). However, the central role is played by the ubiquitin-conjugating enzymes E2M (UBE2M) and E2F (UBE2F), which are part of the E2 enzyme family. Recent understanding of the structure and mechanism of these two proteins provides insight into their physiological effects on apoptosis, cell cycle arrest and genome stability. To treat cancer, it is therefore appealing to develop novel inhibitors against UBE2M or UBE2F interactions with either E1 or E3. In this evaluation, we summarized the existing understanding of E2 interaction with E1 and E3 and reviewed the prospective of using neddylation E2 as a pharmacological target for evolving new anti-cancer remedies.
引用
收藏
相关论文
共 50 条
  • [41] Neddylation positively regulates the ubiquitin E3 ligase activity of parkin
    Um, Ji Won
    Han, Kyung Ah
    Im, Eunju
    Oh, Yohan
    Lee, Kyule
    Chung, Kwang Chul
    JOURNAL OF NEUROSCIENCE RESEARCH, 2012, 90 (05) : 1030 - 1042
  • [42] Phosphodiesterase type 5 inhibitors: discovery and therapeutic utility
    Rotella, DP
    DRUGS OF THE FUTURE, 2001, 26 (02) : 153 - 162
  • [43] Design and discovery of mushroom tyrosinase inhibitors and their therapeutic applications
    Mendes, Eduarda
    Perry, Maria de Jesus
    Francisco, Ana Paula
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (05) : 533 - 554
  • [44] Inhibition of β-Catenin Signaling Involved in the Biological Activities of a Lignan E2S Isolated from Carya cathayensis Fruits
    Xia, Xichun
    Bi, Xiuli
    wu, Wei
    Mou, Yanhua
    Hou, Yue
    Zhang, Kaiqing
    Zhao, Yuqing
    PLANTA MEDICA, 2013, 79 (17) : 1648 - 1652
  • [45] Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
    Yi Wang
    Sui Fang
    Yan Wu
    Xi Cheng
    Lei-ke Zhang
    Xu-rui Shen
    Shuang-qu Li
    Jian-rong Xu
    Wei-juan Shang
    Zhao-bing Gao
    Bing-qing Xia
    Acta Pharmacologica Sinica, 2022, 43 : 781 - 787
  • [46] Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
    Wang, Yi
    Fang, Sui
    Wu, Yan
    Cheng, Xi
    Zhang, Lei-ke
    Shen, Xu-rui
    Li, Shuang-qu
    Xu, Jian-rong
    Shang, Wei-juan
    Gao, Zhao-bing
    Xia, Bing-qing
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (04) : 781 - 787
  • [47] In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors
    Jernigan, Finith E.
    Sun, Lijun
    FUTURE MEDICINAL CHEMISTRY, 2017, 9 (12) : 1309 - 1311
  • [48] AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery
    Baker, Jeremy D.
    Uhrich, Rikki L.
    Strovas, Timothy J.
    Saxton, Aleen D.
    Kraemer, Brian C.
    SLAS DISCOVERY, 2021, 26 (03) : 400 - 409
  • [49] Discovery of novel inhibitors for ECT2 as a novel therapeutic strategy for lung cancer
    Beyer, Tracey E.
    Smith, Rachel M.
    Song, Zuohe
    Gokhale, Vijay
    Moses, Sylvestor A.
    Meuillet, Emmanuelle J.
    CANCER RESEARCH, 2012, 72
  • [50] Discovery and Structure-Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington's Disease
    Prime, Michael E.
    Andersen, Ole A.
    Barker, John J.
    Brooks, Mark A.
    Cheng, Robert K. Y.
    Toogood-Johnson, Ian
    Courtney, Stephen M.
    Brookfield, Frederick A.
    Yarnold, Christopher J.
    Marston, Richard W.
    Johnson, Peter D.
    Johnsen, Siw F.
    Palfrey, Jordan J.
    Vaidya, Darshan
    Erfan, Sayeh
    Ichihara, Osamu
    Felicetti, Brunella
    Palan, Shilpa
    Pedret-Dunn, Anna
    Schaertl, Sabine
    Sternberger, Ina
    Ebneth, Andreas
    Scheel, Andreas
    Winkler, Dirk
    Toledo-Sherman, Leticia
    Beconi, Maria
    Macdonald, Douglas
    Munoz-Sanjuan, Ignacio
    Dominguez, Celia
    Wityak, John
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 1021 - 1046